NEWS
2025.05.22
Info
ExaMD, a Member of the ExaWizards Group, Launches a Gait Analysis AI Application for Medical Institutions — Simplifying Gait Function Visualization with a Smartphone, Collaborative Development with Juntendo University —
2025.04.01
Info
ExaMD, a Member of the ExaWizards Group, obtained the Type II Medical Device Manufacturing and Marketing License, and the Medical Device Sales License – Empowering ExaMD to Develop, Manufacture, and Market Software as a Medical Device (SaMD) –
2025.03.25
Info
Notice Regarding Changes in Directors and Officers
2025.03.18
Info
ExaWizards Holds the First and Second Meetings of the “Committee of Experts on the Suitability of AI”
2025.02.10
Info
ExaWizards’ Wholly Owned Subsidiary, ExaMD AI-Powered Dementia Diagnosis App Using Conversational Audio Designated as a Priority Review Product under Innovative Medical Device Program
2025.01.30
Info
The “RAGOps Template” for Continuously Improving Generative AI Responses Featured on AWS Case Study Page
2025.01.08
Info
“Message from the President” Updated
2024.03.26
Info
ExaWizards has been selected as a partner company to utilize customer data in NTT’s Large Language Model (LLM) “tsuzumi”
2024.03.21
Info
Toyoda Gosei Adopts “exaBase IR Assistant”
– Utilizing Generative AI Technology to Focus on High-Value Information Disclosures –
2024.03.18
Info